<DOC>
	<DOCNO>NCT00657501</DOCNO>
	<brief_summary>This study randomize , double-blind , placebo-controlled , multi-center study safety efficacy LibiGel 300mcg treatment HSDD surgically menopausal woman .</brief_summary>
	<brief_title>Safety Efficacy LibiGelÂ® Treatment Hypoactive Sexual Desire Disorder Surgically Menopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hypokinesia</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Must age 30 65 year Must undergone hysterectomy bilateral salpingooophorectomy A history allergic reaction androgen ( oral patch ) , topical alcohol , component formulation Any systemic skin diseases local skin abnormality area application Diagnosed another primary female sexual dysfunction ( e.g. , Sexual Aversion Disorder , Female Sexual Arousal Disorder ) . A medical condition could affect interfere sexual function Using systemic transdermal gel cream estrogen therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>testosterone</keyword>
	<keyword>hypoactive sexual desire disorder</keyword>
	<keyword>menopause</keyword>
</DOC>